Company profile: Gnubio
1.1 - Company Overview
Company description
- Provider of scalable desktop DNA sequencing systems for diagnostic and applied markets, integrating target selection, DNA amplification, sequencing, and analysis via emulsion-based droplet microfluidics. Offers single-use consumable cartridges and workflows for targeted sequencing and hotspot analysis, with whole genome and transcriptome applications in development.
Products and services
- Microfluidics Technology: Emulsion-based, picoliter-scale droplet microfluidics conducts DNA sequencing reactions inside tiny aqueous drops, architected for scalable, efficient sequencing throughput across diagnostic and applied workflows
- GnuBIO Platform: Desktop-scale sequencer integrates target selection, DNA amplification, sequencing, and analysis in one system, enabling interrogation of single genes, gene panels, and whole genomes
- Targeted Sequencing and Hotspot Analysis: Custom-engineered workflows sequence specific genes and rare variants, running from DNA input to completed results on the GnuBIO platform for hotspot interrogation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Gnubio
Fulcrum Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology therapies targeting rare genetic diseases at their root cause, including losmapimod (a small molecule under investigation for facioscapulohumeral muscular dystrophy) and FTX-6058 (a small molecule designed to increase expression of fetal hemoglobin for treating sickle cell disease and beta-thalassemia).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fulcrum Therapeutics company profile →
Precision BioSciences
HQ: United States
Website
- Description: Provider of ARCUS genome editing technology using sequence-specific nucleases to modify DNA in living cells and tissues, a Manufacturing Center for Advanced Therapeutics for production of advanced therapies, PBGENE-HBV targeting chronic hepatitis B, and partnerships for in vivo gene editing and ex vivo CAR T-cell therapy development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Precision BioSciences company profile →
Integrated DNA Technologies
HQ: United States
Website
- Description: Provider of custom DNA and RNA oligonucleotides with various modifications; CRISPR-Cas9 reagents and tools for genome editing; gBlocks double-stranded gene fragments (125-3000 bp) for gene assembly, qPCR, and NGS; PrimeTime qPCR probes with dye and quencher options for multiplex gene expression analysis; and xGen DNA library prep kits for next-generation sequencing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Integrated DNA Technologies company profile →
Axxam
HQ: Italy
Website
- Description: Provider of integrated drug discovery services from target validation to lead generation, including assay development, high-throughput screening and hit-to-lead profiling, with a focus on small-molecule drugs targeting inflammation. Offers RNA biology platforms, SARS-CoV-2 cell-based and biochemical assays, a 349k-compound AXXDiversity library, and the AXXSense platform for flavors, fragrances and taste modulation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Axxam company profile →
Omega Therapeutics
HQ: United States
Website
- Description: Provider of a proprietary epigenomic programming platform (OMEGA Platform) to develop therapeutics by controlling gene expression; conducts the MYCHELANGELO Phase 1/2 trial in non-small cell lung cancer; runs IND-enabling preclinical studies in inflammation/immunology and other diseases to assess gene targets; and offers an expanded access policy for investigational therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Omega Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Gnubio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Gnubio
2.2 - Growth funds investing in similar companies to Gnubio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Gnubio
4.2 - Public trading comparable groups for Gnubio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →